Abstract

The present invention is directed to methods for modulating or detecting changes in peroxisome proliferator activated receptors (PPARs) and retinoid X receptors (RXR) to: 1) treat certain neuropsychiatric disorders, 2) identify susceptibility to such disorders in a clinical setting, and 3) screen novel pharmacological agents, including retinoids and retinoid derivatives for adverse psychiatric side-effects, and 4) generate certain neuropsychiatric disorders in preclinical conditions.


Claims

Download Citation


Sign in to the Lens

Feedback